Literature DB >> 30145931

Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems.

Varun Balaji1, Senthilvelrajan Kaniyappan1, Eckhard Mandelkow1,2,3, Yipeng Wang1, Eva-Maria Mandelkow1,2,3.   

Abstract

Missorting of MAPT/Tau represents one of the early signs of neurodegeneration in Alzheimer disease. The triggers for this are still a matter of debate. Here we investigated the sorting mechanisms of endogenous MAPT in mature primary neurons using microfluidic chambers (MFCs) where cell compartments can be observed separately. Blocking protein degradation pathways with proteasomal or autophagy inhibitors dramatically increased the missorting of MAPT in dendrites on the neuritic side, suggesting that degradation of MAPT in dendrites is a major determinant for the physiological axonal distribution of MAPT. Such missorted dendritic MAPT differed in its phosphorylation pattern from axonal MAPT. By contrast, enhancing autophagy or proteasomal pathways strongly reduced MAPT missorting, thereby confirming the role of protein degradation pathways in the polar distribution of MAPT. Dendritic missorting of MAPT by blocking protein degradation resulted in the loss of spines but not in overall cell toxicity. Inhibition of local protein synthesis in dendrites eliminated the missorting of MAPT, indicating that the accumulation of dendritic MAPT is locally generated. In support of this, a substantial fraction of Mapt/Tau mRNA was detected in dendrites. Taken together, our results indicate that the autophagy and proteasomal pathways play important roles in fine-tuning dendritic MAPT levels and thereby prevent synaptic toxicity caused by MAPT accumulation. Abbreviations Ani: anisomycin; Baf: bafilomycin A1; BSA: bovine serum albumin; cAMP: cyclic adenosine monophosphate; CHX: cycloheximide; DMSO: dimethyl sulfoxide; DIV: days in vitro; Epo: epoxomicin; E18: embryonic day 18; FISH: fluorescence in situ hybridization; IgG: immunoglobulin; kDa: kilodalton; Lac: lactacystin; LDH: lactate dehydrogenase; MFC: microfluidic chambers; MAPs: microtubule-associated proteins; MAPT/Tau: microtubule-associated protein tau; PVDF: polyvinylidene difluoride; PBS: phosphate-buffered saline; PRKA: protein kinase AMP-activated; RD150: round device 150; RT: room temperature; SDS: sodium dodecyl sulfate; SEM: standard error of the mean; Wor: wortmannin.

Entities:  

Keywords:  Alzheimer disease; MAPT/Tau; autophagy; degradation; microfluidic chambers; proteasome

Mesh:

Substances:

Year:  2018        PMID: 30145931      PMCID: PMC6984766          DOI: 10.1080/15548627.2018.1509607

Source DB:  PubMed          Journal:  Autophagy        ISSN: 1554-8627            Impact factor:   16.016


  69 in total

1.  Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.

Authors:  Natura Myeku; Catherine L Clelland; Sheina Emrani; Nikolay V Kukushkin; Wai Haung Yu; Alfred L Goldberg; Karen E Duff
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

2.  Proteasomes. A molecular census of 26S proteasomes in intact neurons.

Authors:  Shoh Asano; Yoshiyuki Fukuda; Florian Beck; Antje Aufderheide; Friedrich Förster; Radostin Danev; Wolfgang Baumeister
Journal:  Science       Date:  2015-01-23       Impact factor: 47.728

Review 3.  Compromised autophagy and neurodegenerative diseases.

Authors:  Fiona M Menzies; Angeleen Fleming; David C Rubinsztein
Journal:  Nat Rev Neurosci       Date:  2015-06       Impact factor: 34.870

4.  Compartment-Specific Regulation of Autophagy in Primary Neurons.

Authors:  Sandra Maday; Erika L F Holzbaur
Journal:  J Neurosci       Date:  2016-06-01       Impact factor: 6.167

5.  Three distinct axonal transport rates for tau, tubulin, and other microtubule-associated proteins: evidence for dynamic interactions of tau with microtubules in vivo.

Authors:  M Mercken; I Fischer; K S Kosik; R A Nixon
Journal:  J Neurosci       Date:  1995-12       Impact factor: 6.167

6.  Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies.

Authors:  E Sontag; V Nunbhakdi-Craig; G Lee; R Brandt; C Kamibayashi; J Kuret; C L White; M C Mumby; G S Bloom
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

7.  Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.

Authors:  Hans Zempel; Edda Thies; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  J Neurosci       Date:  2010-09-08       Impact factor: 6.167

8.  Pathological Tau Promotes Neuronal Damage by Impairing Ribosomal Function and Decreasing Protein Synthesis.

Authors:  Shelby Meier; Michelle Bell; Danielle N Lyons; Jennifer Rodriguez-Rivera; Alexandria Ingram; Sarah N Fontaine; Elizabeth Mechas; Jing Chen; Benjamin Wolozin; Harry LeVine; Haining Zhu; Jose F Abisambra
Journal:  J Neurosci       Date:  2016-01-20       Impact factor: 6.167

9.  Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1.

Authors:  Edda Thies; Eva-Maria Mandelkow
Journal:  J Neurosci       Date:  2007-03-14       Impact factor: 6.167

10.  Tau isoform expression and regulation in human cortical neurons.

Authors:  Atul Deshpande; Khin May Win; Jorge Busciglio
Journal:  FASEB J       Date:  2008-02-08       Impact factor: 5.191

View more
  8 in total

Review 1.  Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer's Disease.

Authors:  José J Jarero-Basulto; Martha C Rivera-Cervantes; Deisy Gasca-Martínez; Francisco García-Sierra; Yadira Gasca-Martínez; Carlos Beas-Zárate
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-26

Review 2.  Revisiting the Role of GSK3, A Modulator of Innate Immunity, in Idiopathic Inclusion Body Myositis.

Authors:  Manuela Piazzi; Alberto Bavelloni; Vittoria Cenni; Irene Faenza; William L Blalock
Journal:  Cells       Date:  2021-11-21       Impact factor: 6.600

Review 3.  Tau mRNA Metabolism in Neurodegenerative Diseases: A Tangle Journey.

Authors:  Paulo J da Costa; Malika Hamdane; Luc Buée; Franck Martin
Journal:  Biomedicines       Date:  2022-01-23

Review 4.  Tau Ubiquitination in Alzheimer's Disease.

Authors:  Longfei Li; Yanli Jiang; Jian-Zhi Wang; Rong Liu; Xiaochuan Wang
Journal:  Front Neurol       Date:  2022-02-08       Impact factor: 4.003

5.  PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain.

Authors:  Ari W Schaler; Avery M Runyan; Catherine L Clelland; Eric J Sydney; Stephanie L Fowler; Helen Y Figueroa; Seiji Shioda; Ismael Santa-Maria; Karen E Duff; Natura Myeku
Journal:  Sci Transl Med       Date:  2021-05-26       Impact factor: 17.956

6.  FRET-based Tau seeding assay does not represent prion-like templated assembly of Tau filaments.

Authors:  Senthilvelrajan Kaniyappan; Katharina Tepper; Jacek Biernat; Ram Reddy Chandupatla; Sabrina Hübschmann; Stephan Irsen; Sandra Bicher; Christoph Klatt; Eva-Maria Mandelkow; Eckhard Mandelkow
Journal:  Mol Neurodegener       Date:  2020-07-16       Impact factor: 14.195

Review 7.  Glycogen synthase kinase (GSK)-3 and the double-strand RNA-dependent kinase, PKR: When two kinases for the common good turn bad.

Authors:  Manuela Piazzi; Alberto Bavelloni; Irene Faenza; William Blalock
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-06-05       Impact factor: 4.739

8.  Network Pharmacology-Based and Experimental Identification of the Effects of Quercetin on Alzheimer's Disease.

Authors:  Pingfang Qi; Jing Li; Shichao Gao; Yirong Yuan; Yindi Sun; Na Liu; Yuanyuan Li; Gang Wang; Ling Chen; Jing Shi
Journal:  Front Aging Neurosci       Date:  2020-10-23       Impact factor: 5.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.